Other languages JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-23 am EDT			5-day change	1st Jan Change
808 ^JPY	-0.37%		-1.94%	-31.06%

Mar. 21	US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	MT
Mar. 21	JCR Pharmaceuticals Achieves Neurodegenerative Treatment Research Milestone With Alexion	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak	Mar. 21
JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion	Mar. 19
JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes	Feb. 28
JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier	Feb. 14
JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Feb. 08
Asia Markets Remain Mixed as Investors Step Back Following Rally	Dec. 21
Japanese Shares Slip Back into Red as Wall Street Ends Winning Streak Ahead of Key US Data	Dec. 21
JCR Pharmaceuticals' Partner Takeda to Scrap Gene Therapy Collaboration	Dec. 21
JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Announces Discontinuation of Gene Therapy Collaboration	Dec. 20
JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo	Dec. 20
JCR Pharmaceuticals' Metabolic Disease Drug Candidate Granted FDA's Orphan Drug Designation	Dec. 14
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	Dec. 12
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	Dec. 12
Japanese Shares Rebound on Wednesday, Boosted by Automotive Stocks	Nov. 22
JCR Pharmaceuticals' Fiscal H1 Attributable Profit Climbs on Increased Drug Sales	Nov. 21
JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA	23-10-26
JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	23-10-25
JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)	23-09-29
MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Conclude Two Agreements on Mucopolysaccharidosis Type IIIB Treatment	23-09-28
JCR Pharmaceuticals Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-09-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages JCR Pharmaceuticals Co., Ltd.

Equities

4552

JP3701000006

Other languages

Filters